Evidence map›Paper›PMID 34440243›Full record

ArticleBiomedicines2021

GRP78 Overexpression Triggers PINK1-IP

Tatiana Leiva-Rodríguez, David Romeo-Guitart, Mireia Herrando-Grabulosa, Pau Muñoz-Guardiola, Miriam Polo, Celia Bañuls, Valerie Petegnief, Assumpció Bosch, Jose Miguel Lizcano, Nadezda Apostolova and 2 more

Abstract read
In one paragraph

Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. GRP78 Activity Moderation as a Therapeutic Treatment against Obesity.International journal of environmental research and public health · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tatiana Leiva-RodríguezDepartment of Cell Biology, Physiology and Immunology, Institut de Neurociències (INc), Universitat Autònoma de Barcelona (UAB), 08193 Barcelona, Spain.ORCID 0000-0003-0359-0045
David Romeo-GuitartDepartment of Cell Biology, Physiology and Immunology, Institut de Neurociències (INc), Universitat Autònoma de Barcelona (UAB), 08193 Barcelona, Spain.
Mireia Herrando-GrabulosaDepartment of Cell Biology, Physiology and Immunology, Institut de Neurociències (INc), Universitat Autònoma de Barcelona (UAB), 08193 Barcelona, Spain.
Pau Muñoz-GuardiolaDepartment of Biochemistry and Molecular Biology, Institut de Neurociències (INc), Universitat Autònoma de Barcelona (UAB), 08193 Barcelona, Spain.
Miriam PoloService of Endocrinology University Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), 46010 Valencia, Spain.
Celia BañulsService of Endocrinology University Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), 46010 Valencia, Spain.ORCID 0000-0001-8077-7642
Valerie PetegniefDepartment of Brain Ischemia and Neurodegeneration, Institute for Biomedical Research of Barcelona (IIBB), Spanish Research Council (CSIC), Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Assumpció BoschCentro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), 08193 Barcelona, Spain.ORCID 0000-0002-7205-2796
Jose Miguel LizcanoDepartment of Biochemistry and Molecular Biology, Institut de Neurociències (INc), Universitat Autònoma de Barcelona (UAB), 08193 Barcelona, Spain.ORCID 0000-0002-3154-5383
Nadezda ApostolovaCIBERehd, Department de Farmacologia, Facultat de Medicina, Universitat de Valencia, 46010 Valencia, Spain.ORCID 0000-0002-4487-2471
Joaquim ForésHand and Peripheral Nerve Unit, Hospital Clínic i Provincial, Universitat de Barcelona, 08007 Barcelona, Spain.
Caty CasasDepartment of Cell Biology, Physiology and Immunology, Institut de Neurociències (INc), Universitat Autònoma de Barcelona (UAB), 08193 Barcelona, Spain.

Funding

Ministerio de Economía y Competitividad #SAF 2014-59701
6 · The paper itself

Abstract

An experimental model of spinal root avulsion (RA) is useful to study causal molecular programs that drive retrograde neurodegeneration after neuron-target disconnection. This neurodegenerative process shares common characteristics with neuronal disease-related processes such as the presence of endoplasmic reticulum (ER) stress and autophagy flux blockage. We previously found that the overexpression of GRP78 promoted motoneuronal neuroprotection after RA. After that, we aimed to unravel the underlying mechanism by carrying out a comparative unbiased proteomic analysis and pharmacological and genetic interventions. Unexpectedly, mitochondrial factors turned out to be most altered when GRP78 was overexpressed, and the abundance of engulfed mitochondria, a hallmark of mitophagy, was also observed by electronic microscopy in RA-injured motoneurons after GRP78 overexpression. In addition, GRP78 overexpression increased LC3-mitochondria tagging, promoted PINK1 translocation, mitophagy induction, and recovered mitochondrial function in ER-stressed cells. Lastly, we found that GRP78-promoted pro-survival mitophagy was mediated by PINK1 and IP3R in our in vitro model of motoneuronal death. This data indicates a novel relationship between the GRP78 chaperone and mitophagy, opening novel therapeutical options for drug design to achieve neuroprotection.

Indexed as

GRP78/BiPmitophagymotoneuronsneurodegenerationneuroprotection

Identifiers

PMID34440243
PMCPMC8391647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.